Gaucher disease type 2 (BG2) is a rare inherited disorder belonging to a group of lysosomal storage diseases caused by a deficiency of the enzyme glucocerebrosidase. Unlike the more common form of Gaucher disease (type 1), which primarily manifests as hematosarcoma and systemic disorders, Gaucher disease type 2 is characterized by a neuropathic form, occurring mainly in infants and young children. LB2 is a severe disease that progresses from early childhood and leads to significant neurological impairment, including developmental delay, seizures, and death, often within the first two years of life.
History of the disease and interesting historical facts
Gaucher disease was first described in 1882 by the French physician Felix Gaucher. He observed an enlarged liver and spleen in a patient, along with other symptoms that were later classified as symptoms of the disease. Later, in 1965, it was discovered that the disease was due to a defect in glucocerebrosidase. The history of research into Gaucher disease is full of interesting facts; in particular, this disease was one of the first for which a specific enzyme replacement therapy was developed. In 1991, clinical trials were conducted that proved the effectiveness of this therapy, which was an important step forward in the treatment of most forms of the disease.
Epidemiology
The prevalence of Gaucher disease worldwide is estimated to be 1 in 40,000–100,000 births, but the risk is significantly higher in the Ashkenazi Jewish population, at 1 in 500. Type 2 disease is more prevalent among certain ethnic groups, with prevalence reported to be as high as 1 in 200 in some communities.
Genetic predisposition to this disease
Gaucher disease type 2 is caused by mutations in the GBA gene, which is located on chromosome 1q21. The defect in this gene results in insufficient production of the enzyme glucocerebrosidase, which in turn causes substrate accumulation in lysosomes. Overall, more than 400 different mutations are known to be associated with the disease, including point mutations, deletions, and insertions. The most common genetic variants include N370S and L444P, but type 2 is characterized by a sharp increase in their occurrence in the Caucasian population.
Risk factors for the development of this disease
Risk factors for type 2 Gaucher disease are mainly related to genetic predisposition. These factors include:
- Hereditary predisposition (especially in Ashkenazi Jewish families).
- Family history of Gaucher disease.
- Certain mutations in the GBA gene.
- Impact of environmental factors (in rare cases).
Research also suggests that a higher risk may be seen in patients with a personal history of other lysosomal storage diseases.
Diagnosis of this disease
The main goal of diagnosing Gaucher disease type 2 is to identify the disease early so that treatment can begin. The main symptoms include:
- Enlargement of the liver and spleen.
- Neurological disorders (developmental delay, epilepsy).
- General deficiencies in the body (fatigue, abnormal coagulation).
The following studies are carried out for diagnostics:
- Laboratory tests: determination of glucocerebrosidase enzyme activity in leukocytes or plasma.
- Radiological examinations: ultrasound, CT or MRI to diagnose damage to organs and the nervous system.
- Other diagnostic tests include genetic testing to detect mutations in the GBA gene.
- Differential diagnosis: exclusion of other diseases with similar symptoms, such as Niemann-Pick disease and other lysosomal dysfunctions.
Treatment
Treatment for Gaucher disease type 2 is multi-stage and depends on the stage of the disease. General principles of treatment include:
- Pharmacological treatment: enzyme replacement therapy (ERT) if available to restore glucocerebrosidase levels.
- Surgical treatment: Splenectomy may be performed in severe cases to relieve symptoms.
- Other treatments: supportive care, including physical therapy and medication to control neurological symptoms.
Clinical trials of new therapies are ongoing, suggesting the need for an individualized treatment approach for each patient.
List of medications used to treat this disease
Among the main drugs used to treat Gaucher disease are:
- Imiglucerase (Cerezyme)
- Velaglucerase alfa (VPRIV)
- Taliglucerase alfa (Elelyso)
- Symptomatic drugs for the correction of neurological disorders.
- Supportive therapy (psychological assistance, physiotherapy).
Disease monitoring
Monitoring the course of Gaucher disease type 2 includes regular follow-up examinations to assess the patient's condition. The main stages of monitoring are:
- Assessment of clinical symptoms and general health status.
- Laboratory tests to monitor enzyme activity.
- Radiological studies to monitor changes in organs.
- Prognosis: The disease has a poor outcome without treatment, but early intervention can improve quality of life and prolong it.
- Ose complications: severe neurological consequences leading to disability, as well as organ problems due to the accumulation of glucocerebrosidase in lysosomes.
Age-related features of the disease
Gaucher disease type 2 has different age-related manifestations:
- In neonates: symptoms appear in the first months of life, often with severe neurological impairment and rapid progression.
- In young children: developmental delays and progressive neurological problems are observed.
- In adolescents and adults: cases are extremely rare, clinical manifestations can vary from mild to severe, but cases with partial persistent symptoms are possible.
Questions and Answers
- How is Gaucher disease type 2 transmitted? Gaucher disease type 2 is inherited in an autosomal recessive manner, meaning that both copies of the GBA gene contain a mutation.
- What are the main symptoms of Gaucher disease type 2? The main symptoms include enlargement of the liver and spleen, developmental delays, neurological impairment and seizures.
- Is it possible to avoid the disease? There is no way to prevent the disease, but genetic counseling can help identify risks in expectant parents.
- What is the life expectancy for Gaucher disease type 2? Without treatment, life expectancy is temporarily limited, often resulting in death in the first 2–3 years of life.
- How effective is enzyme replacement therapy? The effectiveness of ERT varies depending on the stage of the disease, but depending on the nature of the symptoms, it can significantly improve the quality of life.
Advice from Dr. Oleg Korzhikov
If you have symptoms such as enlarged liver and spleen or any signs of neurological disorders, it is recommended to see a doctor as soon as possible for diagnosis. Remember that support from relatives, proper nutrition and regular medical check-ups are of great importance to improve the overall condition and quality of life with Gaucher disease type 2. It is important to monitor changes in health and promptly respond to new symptoms.
